Back to News
Market Impact: 0.12
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
Source: PR Newswire
ESG & Climate PolicyGreen & Sustainable FinanceHealthcare & Biotech
WuXi Biologics was named to the 2026 Forbes China ESG 50 list, recognized for sustainable-development performance, Green CRDMO solutions and ESG digital innovation. The recognition supports the company's ESG credentials but contains no financial results, guidance, or material operating update.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
More News
- Premarket movers: Intel jumps on SK Hynix memory-chip talks, J.B. Hunt slides
- Japan has a problematic age gap: 100,000-plus residents are over 100 and the pension system is buckling
- US DFC approves €85 million loan to Ukraine’s DTEK
- The MLB and its Dominican pipeline is selling false promises and shady contracts to children as young as 11
- Arrowhead Pharmaceuticals at H.C. Wainwright: launch and pipeline widen
- More Than 500 Customers Back Union Pacific-Norfolk Southern Combination as a Catalyst for American Growth
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Portfolio Monitoring: Build an Alert Policy Analysts Can Audit
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)